CTIS2023-506137-30-00进行中（未招募）1 期
A randomized, multi-centre, double-blind, phase II clinical trial of dose finding of Montelukast in patients with erosive osteoarthritis of the hands. HOME study. - FMLD-ARSIDOS-55_FII
Farmalider S.A.0 个研究点目标入组 50 人开始时间: 2023年8月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patients who provide written informed consent and are willing to comply with all scheduled visits and procedures required by the study., Patients = 18 years at the time of the baseline visit., Patients with erosive osteoarthritis of the interphalangeal joints of the hand with significant clinical activity according to Anandarajah criteria., Patients with VAS pain of the most affected hand = 50 mm at the baseline visit., Patients with repercussion in functionality of the most affected hand evaluated with a score =2 in the question number 12 (carrying a full pot with one hand) of the function subscale of the AUSCAN Questionnaire.
排除标准
- •History of fibromyalgia and/or chronic fatigue syndrome., Patient being treated with NSAIDs* and/or analgesics (except paracetamol) or colchicine within 7 days prior to the baseline visit. The use of paracetamol will be allowed up to 24 hours prior to the start of study treatment. *The sporadic use of Ibuprofen in case of an intercurrent disease other than EHOA will be allowed up to 96 hours prior to the screening visit (visit 0), or, to the visit 1. Maximum daily dose of ibuprofen allowed will be 1200mg., Patient with a history of allergy or hypersensitivity to the study medication, rescue medication or any of its excipients., Patient intolerant to study medication due to galactose intolerance, lactase insufficiency, or glucose-galactose malabsorption., Pregnant or lactating women., Women of childbearing age and sexually active (excluded from this definition are women whose date of last menstruation is greater than one year from inclusion in this study and those who have undergone a tubal ligation or hysterectomy), who do not agree to take contraceptive measures during the clinical trial. Contraceptive measures include barrier methods, hormonal contraception, intrauterine device (IUD), or sexual abstinence. The investigator is responsible for determining whether the subject has adequate birth control for study participation., Patient currently included in or who have participated in a clinical trial with medicines or health products in the 3 months prior to the baseline visit., Patients with scheduled surgery during the clinical trial, History of drug or alcohol abuse during the 12 months prior to the baseline visit., Patient with pathologies that according to medical criteria discourage their participation in the study, such as poorly controlled neuropsychiatrics diseases, severe heart disease, liver failure, kidney failure, active malignancies, poorly controlled endocrine-metabolic diseases, coagulopathies, active gastrointestinal ulceration, active infection, epilepsy, and immunocompromised patients., Patient with a history of concurrent rheumatic articular diseases (history and/or current presence of signs) that could lead to a misinterpretation or interfere in the evaluation of efficacy in pain, such as chondrocalcinosis, Paget's disease of the ipsilateral extremity in relation to the affected hand, rheumatoid arthritis, aseptic osteonecrosis, gout, septic arthritis, ochronosis, acromegaly, hemochromatosis, Wilson's disease, osteochondromatosis, seronegative spondyloarthropathy, mixed connective tissue disease, collagen vascular disease, psoriasis and disease Inflammatory bowel (Crohn's disease or Ulcerative Colitis)., Pain in another part of the body that could interfere with the evaluation and results of the study according investigator criteria., Patient taking corticosteroids (oral or injectable) within 4 weeks prior to the baseline visit, or methotrexate, hydroxychloroquine or SYSADOAs (Slow-Acting Drugs for the Symptomatic Treatment of Osteoarthritis) within 12 weeks prior to the baseline visit., Patients who have used intra-articular hyaluronic acid (in the study hand) during the 24 weeks prior to the baseline visit., Patient undergoing radioactive synoviorthesis (in the study hand)., Patient being treated with other disease-modifying anti-rheumatic biological drugs., Patient being treated with any other medication contraindicated due to risk of interactions with study medication.
研究者
相似试验
已完成
不适用
A multi-center, randomized, double-blind, phase III clinical trial to evaluate the efficacy and safety of Nebivolol/Rosuvastatin combination treatment in patients with concomitant Hypertension and HyperlipidemiaDiseases of the circulatory systemKCT0002148Elyson Pharmaceutical276
进行中（未招募）
1 期
A multi-center, randomized, double-blind, phase II trial with intraindividual comparison to assess superiority of Soventol HydroCortisonACETAT 1 % Cremogel versus vehicle on lesional skin in patients with mild atopic eczema, seborrheic eczema or stasis dermatitis and to assess safety of Soventol HydroCortisonACETAT 1 % CremogelEUCTR2017-000984-34-DEMedice Arzneimittel Pütter GmbH & Co KG50
进行中（未招募）
不适用
Comparison of defined skin parameters in two comparable lesional skin areas after topical treatment with Soventol HydroCort 1% cream or vehiclemanifest atopic dermatitis diagnosed according to Hanifin and Rajka, or seborrheic eczema or stasis dermatitisMedDRA version: 14.1Level: PTClassification code 10041955Term: Stasis dermatitisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 14.1Level: LLTClassification code 10062813Term: Seborrheic eczemaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 14.1Level: LLTClassification code 10003641Term: Atopic eczemaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2013-000715-25-DEMEDICE Arzneimittel Pütter GmbH & Co.KG
进行中（未招募）
不适用
A phase II randomized, double-blind, multicentre, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking methotrexateLevel: PTClassification code 10039073Rheumatoid arthritisEUCTR2005-002421-31-GBArakis Ltd292
进行中（未招募）
1 期
This multicenter, randomized, double-blind, phase II study aims to show improvement in the rate of mucositis/stomatitis (WHO´s OTS) grade 2-4 at 12 weeks after start of treatment by comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema starting with a low dose over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.Advance Breast cancer under endocrine treatmentMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 100000004864EUCTR2014-005126-35-DEGBG Forschungs GmbH156